Opportunity Identification

we have experience and expertise

Centralyze is an Investment Platform for high-value innovative biotechnologies, each of which specifically addresses the world's major diseases. We custom build every Centralyze company is built around leading research and development teams with a clear path to market. We bring confidence to investors by implementing our unique Petri Process: Originate, Engage, Capitalise and Commercialise.

Commercialisation Support

we support innovations to thrive

Centralyze understands the risks all investors face today, and the increasing approach for diversification. We curate biotechnology commercialisation opportunities that sit outside of traditional asset classes. Complementarily, Centralyze supports each company through the entirity of the commercialisation process. This is achieved through a suite of services, which complement those of the development team.

Accelerating Life Sciences

  • Pharmaceutical
  • Medical Device
  • Medical Diagnostic
  • Gene Therapy

A New Way to Originate. Capitalise. Commercialise.


Centralyze is an Investment Platform for high-value innovative biotechnologies, each of which specifically addresses the world's major diseases.

We custom builds every Centralyze Company to contain world-leading research and development teams.

We bring confidence to investors by implementing our unique Centralyze Process: Originate, Engage, Capitalise and Commercialise.

Originate

Centralyze performs due diligence of select institutional IP through independent scientific, patent and market analysis.

Centralyze develops with seed investment, commercialisation plan development, assignment of IP, corporate structuring and exit partner engagement.

Capitalise

Approved investors are invited to invest in the equity of our portfolio companies.

Milestone-based investment allows for a broad range of investors to come in at their preferred research stage and risk level.

Commercialise

Our portfolio companies receive back office and ongoing commercialisation support.

Investors are supported by company oversight, reporting and exit opportunity identification as the commercialisation concludes.

Upon successful completion of their commercialisation plan, each portfolio company is exited, whether it be a pharmaceutical company, venture capital, or through an IPO.

Do you want to learn more about us?

Philip Crealy

Director, Translational Research

Vivian Stephens

Director, Business Services

Robert Xi

Analyst

Samuel Kang

Chief Technology Officer

Adrian Hondros

Advisor - Innovation

Vivian Stephens

Advisor - M&A

Ashley Durrant

Advisor - Communications

Want to be part of our team?

If so, click to join now, and be part of our dynamic team!